The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Production issues with Pfizer’s injectable version of naloxone, a lifesaving overdose reversal drug, has caused a shortage of the drug, affecting healthcare providers across the country, The Boston ...

Just two months after getting emergency use authorization from the FDA, Pfizer says they expect to greatly speed up production of their COVID-19 vaccine, cutting production time by almost half. In ...

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...

Pfizer CEO Albert Bourla discusses Pfizer’s Q4 adjusted earnings and the competitive landscape for weight-loss drugs on ‘The ...

U.S.-based pharmaceutical giant German biotech company BioNTech were already collaborating to come up with a flu vaccine ...

Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...